U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT06806228) titled 'Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)' on Jan. 26.
Brief Summary: The objective of this pilot study is to evaluate the efficacy of adding S-Gboxin to standard RT/TMZ treatment protocols in patients with glioblastoma multiforme (GBM) or midline glioma (DMG), regardless of their mutation status
Study Start Date: Feb. 01
Study Type: INTERVENTIONAL
Condition:
Glioblastoma Multiforme
Diffuse Midline Glioma, H3 K27M-Mutant
Gliosarcoma
Giant Cell Glioblastoma
GBM
Intervention:
BIOLOG...